instruction
stringclasses 1
value | input
stringlengths 17
568
| output
stringlengths 1
80
|
|---|---|---|
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM. | Cerebral haemorrhage |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation. | Congenital cerebrovascular anomaly |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke. | Cerebrovascular accident |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation. | Cerebral haemorrhage |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Rapid onset of quetiapine-induced diabetic ketoacidosis in an elderly patient: a case report. | Diabetic ketoacidosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report a case of reversible DKA and new-onset DM that developed in a demented patient who was treated with quetiapine for 14 days. | Diabetic ketoacidosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse. | Leukostasis syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Eruptive epidermoid cysts resulting from treatment with imiquimod. | Dermoid cyst |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | METHODS: A 79-year-old woman being treated with imiquimod 5 days per week for a nodular basal cell developed a verrucous plaque over the treatment area after 7 weeks of therapy. | Skin papilloma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The multiple comedones and ruptured epidermoid cysts are newly reported adverse effects of imiquimod therapy. | Acne |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report an unusual case of massive fluoxetine ingestion resulting in neurological and cardiovascular toxicity resulting in death. | Death |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Hepatocellular damage following therapeutic intravenous iron sucrose infusion in a child. | Hepatocellular injury |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The case reported here is of a child given a large dose of intravenous iron sucrose (16 mg/kg) over 3 hours, who subsequently developed features of systemic iron toxicity. | Systemic toxicity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature. | Amnesia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently. | Retrograde Amnesia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Transient global amnesia after clioquinol: five personal observations from outside Japan. | Transient global Amnesia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection. | Arthritis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids. | Arthritis bacterial |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Septic knee arthritis after intra-articular hyaluronate injection. | Arthritis bacterial |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Acute dystonia induced by lamivudine. | Dystonia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | ADR induced by drug treatment can be a side effect of treatment with antipsychotic drugs and other drugs; however, there have been no reports of lamivudine-induced ADR in the English literature. | Dystonia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The authors report two cases of acute dystonic reactions (ADRs) as a side effect of lamivudine. | Dystonia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The authors think that although lamivudine is widely used and well tolerated, it can cause ADRs, which are reversible after drug withdrawal. | Dystonia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. | Pulmonary fibrosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone. | Affective disorder |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Risperidone-induced psychosis and depression in a child with a mitochondrial disorder. | Depression |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice. | Radiation myelopathy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation. | Pericardial Effusion |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Gemcitabine therapy has been associated with radiation recall reactions when used in the treatment of carcinoma. | Recall phenomenon |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Physicians should be aware of the potential for developing a gemcitabine-induced radiation recall reaction resulting in hemodynamically significant pericardial effusion. | Pericardial Effusion |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report four cases of hemodynamically significant pericardial effusion in patients with refractory lymphoma who were receiving gemcitabine, all of whom had a history of mediastinal radiation without subcarinal blocking. | Pericardial Effusion |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A patient with generalized MG was effectively managed with MM but developed CNS lymphoma after 3 years of treatment. | Central nervous system lymphoma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. | Central nervous system lymphoma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Primary CNS lymphoma regressed on withdrawal of MM. | Central nervous system lymphoma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Baclofen withdrawal: a cause of prolonged fever in the intensive care unit. | Pyrexia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Baclofen withdrawal syndrome resulting from underdosing of oral baclofen should be considered as a potential source of prolonged fever in the intensive care unit. | Withdrawal syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The patient continued to have fever and autonomic instability without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral baclofen. | Autonomic nervous system imbalance |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report a case of baclofen withdrawal syndrome resulting from oral baclofen underdosing. | Withdrawal syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved. | Eosinophilia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease. | Eosinophilic pneumonia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia. | Eosinophilic pneumonia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Can propofol precipitate pancreatitis in patients with Cushing's syndrome? | Pancreatitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Since elevated cortisol levels in Cushing's disease poses a threat for pancreatitis, there is a possibility that patients with Cushing's disease might be more prone to acute pancreatitis following propofol administration. | Pancreatitis acute |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a serotonin syndrome and a focal seizure) of severe lithium-induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic. | Partial seizures |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection. | B-cell lymphoma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Recently, CD20-negative tumors have been described after Rituximab therapy. | B-cell lymphoma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion. | angio-OOedema |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan. | angio-OOedema |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | She died within six weeks of developing congestive heart failure coupled with liver failure due to haemosiderosis despite regular use of desferrioxamine. | Cardiac failure congestive |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Transfusion haemosiderosis inspite of regular use of desferrioxamine: case report. | Haemochromatosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | One of the side-effects of intravitreal triamcinolone is the development of cataract, and it is known that cataract extraction can exacerbate macular degeneration. | Cataract |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration. | Cataract |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy. | Rhabdomyolysis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride. | Rhabdomyolysis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy. | Rhabdomyolysis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Acute myocardial ischemia following accidental intravenous administration of epinephrine in high concentration. | Myocardial ischaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We present a case of acute epinephrine toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously. | Myocardial ischaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome. | Restless legs syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia. | Muscle contractions involuntary |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The major side effect of infliximab is infection. | Infection |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This report describes a probable case of infliximab-induced membranous nephropathy. | Glomerulonephritis membranous |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Linezolid-induced dyserythropoiesis: chloramphenicol toxicity revisited. | Anaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report here two cases of dyserythropoietic anaemia associated with long-term linezolid use that share striking similarities to chloramphenicol-associated myelotoxicity. | Anaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A selective association between fluoxetine and extensive, prominent eye movements in nonrapid eye movement (NREM) sleep was detected, utilizing Fisher's exact one-tailed statistic (p less than 0.00001 for each comparison). | Sleep disorder |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | In addition, a 31-year-old man with obsessive-compulsive disorder developed RBD soon after starting fluoxetine therapy, which persisted at PSG study 19 months after fluoxetine discontinuation. | Sleep disorder |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. | Sleep disorder |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Because of serious side effects of an increase in the QT interval causing torsades de pointes, dofetilide must be initiated with close monitoring of the QT interval in an inpatient setting. | Torsade de pointes |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale. | Myocardial ischaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report marked QT prolongation and torsades de pointes in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with dofetilide for atrial fibrillation. | Myocardial ischaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Prominent positive U waves appearing with high-dose intravenous phenylephrine. | Electrocardiogram abnormal |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug. | Electrocardiogram abnormal |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems. | Hepatotoxicity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Sirolimus-associated hepatotoxicity in the kidney graft recipient. | Hepatotoxicity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient. | Hepatotoxicity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | CASE REPORT: We present a case of a 28-yr-old male who developed a severe case of nephrotic syndrome while being treated for relapsing/remitting Multiple Sclerosis (RRMS) with weekly injections of interferon beta 1a. | Nephrotic syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a. | Nephrotic syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | SUBSEQUENT COURSE: The nephrosis resolved almost completely once the interferon was stopped and after immunosuppressive treatment. | Nephrotic syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This latest (third) report suggests that the safety profile should be reexamined and at least raises the question of potential renal toxicity of interferons in MS. | Nephropathy toxic |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Capecitabine-induced multifocal leukoencephalopathy: a report of five cases. | Progressive multifocal leukoencephalopathy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy. | Progressive multifocal leukoencephalopathy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 56-year-old white woman with a diagnosis of reactive depression developed severe UI after a 30 days' treatment with venlafaxine 75 mg/day. | Urinary Incontinence |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The authors report a case of urinary incontinence (UI) that occurred in a woman after administration of venlafaxine. | Urinary Incontinence |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Venlafaxine-induced urinary incontinence resolved after switching to sertraline. | Urinary Incontinence |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Diagnosis of hypothyroidism during treatment can be difficult because of the common side effects of alpha interferon. | Hypothyroidism |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. | Hypothyroidism |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon. | Thyroid disorder |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported. | Hypothyroidism |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Atrial fibrillation after vardenafil therapy. | Atrial fibrillation |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil. | Atrial fibrillation |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We describe a case of infection with Mycobacterium abscessus in a 67-year-old woman receiving infliximab as a component of her therapy for RA. | Mycobacterium abscessus infection |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy. | Cardiomyopathy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Reversible cardiomyopathy caused by administration of interferon alpha. | Cardiomyopathy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | In this case senna was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related liver injury. | Liver injury |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Subacute cholestatic hepatitis likely related to the use of senna for chronic constipation. | Hepatitis cholestatic |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report a case of senna-induced cholestatic hepatitis which was not diagnosed at presentation. | Hepatitis cholestatic |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Based on the history and clinical features, a diagnosis of insulin-induced lipohypertrophy was made. | Lipohypertrophy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Insulin-induced lipohypertrophy: report of a case with histopathology. | Lipohypertrophy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Thus, the possible in vivo effects of insulin on adipocytes were clearly observed in this case of insulin-induced lipohypertrophy. | Lipohypertrophy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | To our knowledge, this is the first report of insulin-induced lipohypertrophy with detailed histological examinations. | Lipohypertrophy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia. | Diabetes mellitus |